Bladder cancer (BC) patients often have comorbidities, limited treatment options and thus a poor prognosis. Patients with BC often present with comorbidities that challenge the patients’ ability to receive oncological treatment and trouble the completion of treatment due to increased toxicity. Early management of toxicity using patient-reported outcomes (PROs) during treatment has in previous studies in general cancer populations shown to improve adherence to treatment, improve quality of life and overall survival. To test this approach in the BC population requires knowledge about quality of life (QoL) and symptoms during treatment.
The overall aim of this PhD thesis was to test the hypothesis that the active use of PROs during treatment can improve outcomes for BC patients. We performed six studies under this aim.
This PhD presents new knowledge about QoL, PRO symptoms and their correlations in BC patients receiving medical oncological treatment. Electronic PRO reporting was found feasible but further work for handling of PROs by the clinicians is warranted for successful implementation in daily clinic. Finally, a PRO item set has been defined for use during treatment for the BC patients and the initiated randomized study will show whether this tool can improve outcomes and prognosis.
Place of employment
Date and place of defense
11th of June 2020, Rigshospitalet
Christoffer Johansen, Professor, consultant, DMSc, Department of Oncology, Rigshospitalet
Helle Pappot, Professor, consultant, DMSc, Department of Oncology, Rigshospitalet
Henriette Lindberg, consultant, PhD, Department of Oncology, Herlev Hospital